Replimune Group Stock Price, News & Analysis

Replimune Group, Inc. (NASDAQ: REPL) announced the appointment of Christopher Sarchi as Chief Commercial Officer and Sushil Patel, Ph.D., as Chief Strategy Officer, effective immediately. These leadership changes aim to enhance commercial planning ahead of the expected 2024 launch of RP1. Sarchi brings extensive oncology experience, including successful drug launches, while Patel will focus on global commercialization strategies. The company is pioneering oncolytic immunotherapies to transform cancer treatment.

Replimune Group, a clinical-stage biotechnology company focused on oncolytic immunotherapies, will have CEO Philip Astley-Sparke present at the 41^st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:45 AM PT in San Francisco. The event will be broadcasted via webcast, available on their website, with a replay accessible for 30 days. Replimune's innovative RPx platform utilizes a robust HSV-1 backbone, aiming to enhance immune response against tumors, showcasing potential synergy with various cancer treatments.

BOSTON, Dec. 08, 2022 - Replimune Group, Inc. (Nasdaq: REPL) has announced the pricing of a public offering of 5,374,486 shares of common stock at $23.50 per share and pre-funded warrants for 4,200,000 shares at $23.4999 each. The total gross proceeds are expected to be approximately $225 million, before expenses. This offering is managed by J.P. Morgan and others, with a closing date of December 13, 2022, pending customary conditions. Replimune's innovative approach targets cancer treatment through its proprietary RPx platform, enhancing immunogenic responses and potentially interacting synergistically with existing therapies.

Boston, Dec. 07, 2022 - Replimune Group, Inc. (Nasdaq: REPL) has announced a proposed public offering of $125 million in common stock and pre-funded warrants. The offering includes an option for underwriters to buy an additional $18.75 million in shares. J.P. Morgan and SVB Securities are serving as joint book-running managers. This offering will follow a previously filed shelf registration statement. Adverse market conditions may impact the timing and completion of this offering.

Replimune Group announced promising results from the IGNYTE clinical trial of RP1 combined with nivolumab for anti-PD1 failed melanoma, showing an overall response rate (ORR) of 36% and a complete response (CR) rate of 20% among 75 patients. The trial demonstrated clinically meaningful activity, especially in advanced cases. Furthermore, safety data revealed a favorable profile with mostly mild side effects. Replimune aims to expand its cancer treatment franchise with RP1 and leverage collaborations to expedite development in various cancer types.

Replimune Group, Inc. (NASDAQ: REPL) has announced a collaboration with Roche to advance its RP2/3 program for treating colorectal cancer (CRC) and hepatocellular carcinoma (HCC). The agreement includes cost sharing for clinical trials, with Roche supplying its FDA-approved drugs, atezolizumab and bevacizumab. This collaboration aims to enhance treatment options for patients and is aligned with Replimune's strategy to partner with industry leaders. The Phase 2 clinical trials are set to begin in the first half of 2023, focusing on various cancers.

Replimune Group, a clinical-stage biotechnology company based in Woburn, MA, announced a fireside chat presentation at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 1:00 PM ET. The company focuses on developing tumor-directed oncolytic immunotherapies utilizing its proprietary RPx platform, which employs a potent HSV-1 backbone. This platform aims to induce systemic anti-tumor responses by killing tumors and altering the tumor microenvironment. Replimune was founded in 2015 and is publicly traded on NASDAQ under the symbol REPL.

Replimune Group Inc. (NASDAQ: REPL) is set to host an investor event on December 7, 2022, at 8:00 AM ET to present preliminary data from the six-month follow-up of its IGNYTE clinical trial involving RP1 and Opdivo® for melanoma patients who failed anti-PD1 therapy. The event will also explore the commercial potential of RP1 in skin cancer and provide updates on the RP2 and RP3 programs. Live access to the event will be available on the company’s website, with a replay option thereafter.

Replimune Group, Inc. (NASDAQ: REPL) reported its fiscal Q2 2022 results, highlighting significant progress in clinical trials for RP1, a novel oncolytic immunotherapy. The company completed enrollment in the CERPASS clinical trial for cutaneous squamous cell carcinoma (CSCC) and expects primary analysis data by H1 2023. Additionally, it secured a $200 million term loan extending its cash runway into 2025. Despite a net loss of $43.1 million for the quarter, an increase from the previous year’s loss, Replimune remains focused on its pipeline and upcoming data releases.